| 1 |
Chen CH, Shen CH, Wei KL, Xu HW, Chen WM, Chang KC, Huang YT, Hsieh YY, Lu SN, Hung CH, Chang TS. Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy. Diagnostics (Basel) 2023;13. [PMID: 36766578 DOI: 10.3390/diagnostics13030473] [Reference Citation Analysis]
|
| 2 |
Dalbeni A, Villani R, Bevilacqua M, Sacco F, Faccincani D, Cattazzo F, Cavallone F, Mantovani A, Ceruti V, Ieluzzi D, Paon V, Mantovani A, Serviddio G, Sacerdoti D. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience. J Dig Dis 2022;23:324-30. [PMID: 35700113 DOI: 10.1111/1751-2980.13103] [Reference Citation Analysis]
|
| 3 |
Zhou Y, Xie W, Zheng C, Liu L, Chen Z, Wang X. Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). Clin Endocrinol (Oxf) 2021. [PMID: 34913180 DOI: 10.1111/cen.14660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 4 |
Abdo M, Rabiee A, Abdellatif Z, Abdel Alem S, Moustafa A. Impact of sustained virological response on metabolic disorders in diabetic chronic hepatitis C virus patients after treatment with generic sofosbuvir and daclatasvir. Eur J Gastroenterol Hepatol 2021;33:1588-94. [PMID: 32804853 DOI: 10.1097/MEG.0000000000001903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Schlevogt B, Boeker KHW, Mauss S, Klinker H, Heyne R, Link R, Simon KG, Sarrazin C, Serfert Y, Manns MP, Wedemeyer H. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C-Results from the German Hepatitis C-Registry (DHC-R). Biomedicines 2021;9:1495. [PMID: 34680612 DOI: 10.3390/biomedicines9101495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Gitto S, Cursaro C, Bartoli A, Margotti M, Andreone P. Hepatitis C: clinical management and debated issues. Minerva Med 2021;112:228-37. [PMID: 33319975 DOI: 10.23736/S0026-4806.20.07208-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 7 |
Collins LF, Adekunle RO, Cartwright EJ. Metabolic Syndrome in HIV/HCV Co-infected Patients. Curr Treat Options Infect Dis 2019;11:351-71. [PMID: 32030090 DOI: 10.1007/s40506-019-00207-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 8 |
Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci 2020;17:892-902. [PMID: 32308542 DOI: 10.7150/ijms.43079] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 9 |
Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 11.3] [Reference Citation Analysis]
|
| 10 |
Kim BK, Ahn SH. The remaining challenges of HCV treatment in the direct-acting antivirals era. J Gastroenterol Hepatol 2019;34:1891-2. [PMID: 31724229 DOI: 10.1111/jgh.14916] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
